News | August 30, 2025
MHRA approves UK’s first new type of antibiotic for urinary tract infections
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
Treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit
Merger is expected to streamline operations and provide unified management focus, driving efficiency and strategic alignment
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
With the addition of Phase II (~91 KL) in Q1 FY26, the combined capacity of the block now stands at ~200 KL
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
Triggering global regulatory submissions this year for the treatment of obesity
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Subscribe To Our Newsletter & Stay Updated
